From CRISPR to National Security: How Rare Diseases Became America’s Next Strategic Industry

As 2026 begins, North America is moving toward a “bespoke” future, where the primary hurdle is no longer the science of CRISPR or mRNA, but a race against the clock. In the United States, rare diseases affect approximately 30 million Americans—roughly 1 in 10. The human impact remains devastating: 30% of children with a rare condition will not live to see their fifth birthday, and the average “diagnostic odyssey” in the U.S. and Canada still spans 4 to 6 years, during which families bounce between an average of eight different physicians.

However, the conversation in Washington and across U.S. biotech hubs has taken a sharp turn toward national security. With the December 2025 signing of the BIOSECURE Act, the U.S. is formally decoupling its drug development pipeline from “biotechnology companies of concern.” Moreover, in Washington, rare disease policy is increasingly viewed through the lens of biomedical security. Advanced therapies rely on sensitive genomic data, specialized manufacturing, and tightly coupled regulatory systems—assets now seen as strategically comparable to semiconductors or energy infrastructure. The concern is not hypothetical: dependence on foreign trial sites, data platforms, or manufacturing partners creates vulnerabilities that extend beyond healthcare into economic resilience and national preparedness. Rare diseases, once a peripheral policy issue, have become a proving ground for whether the U.S. can retain control over the most advanced layers of its biomedical stack. This legislative shift highlights a growing consensus: biotechnology is the new semiconductor industry. For the U.S. to remain the global leader in rare disease cures, it could reshore its manufacturing and protect its genomic data, all while drastically lowering the cost of innovation to stay competitive with a rapidly expanding Chinese biotech sector.

The “Blockbuster Orphan” and Execution at Scale

At the 44th Annual J.P. Morgan (JPM) Healthcare Conference in January 2026, the industry narrative shifted from “cautious optimism” to “aggressive execution.” Rare diseases took center stage, no longer viewed as niche scientific curiosities but as major growth engines for the next decade.

• Capital in the Spotlight: Analysts at JPM highlighted the rise of the “Blockbuster Orphan.” Major players like BioMarin—which recently paid nearly $5 billion for Amicus Therapeutics—are proving that high unmet need justifies premium pricing and robust reimbursement.
• Efficiency Through AI: Medable debuted its Agentic AI-powered “TMF Agent” at the conference, designed to automate the labor-intensive documentation that typically bogs down small-scale trials. By using AI to ingest and classify trial data, developers are cutting the “tactical bottlenecks” that previously made rare disease research cost-prohibitive.
• The “Execution Year”: Firms like Rocket Pharmaceuticals and REGENXBIO described 2026 as a “pivotal year of execution,” with multiple gene therapies for conditions like Hunter syndrome and Danon disease moving toward final regulatory readouts.

The renewed focus on rare diseases is not being driven by a single conference or investment cycle, but by a convergence of structural pressures facing the U.S. healthcare and innovation system. Rare diseases sit at the intersection of national security, industrial policy, and regulatory reform: they rely on advanced genomic science, require protected data infrastructure, benefit from reshored manufacturing, and demand regulatory models that favor speed over scale. As traditional blockbuster drugs face patent cliffs and rising development costs, rare disease programs offer the U.S. a strategic advantage—high clinical value, defensible pricing, and tighter alignment with emerging regulatory frameworks. The momentum seen across biotech hubs and capital markets in 2026 reflects this recalibration, as rare diseases move from a humanitarian edge case to a core pillar of America’s biomedical strategy.

The FDA’s Regulatory Pivot: The Rare Disease Innovation Hub

This strategic realignment is now being formalized at the regulatory level, where the FDA is rewriting how evidence is generated and evaluated for rare disease therapies. Launched in 2025 and now fully operational in early 2026, the FDA’s Rare Disease Innovation Hub is dismantling the biggest barrier in the field: the requirement for large-scale Phase 3 trials. For ultra-rare conditions, finding the hundreds of patients required for a traditional study is often a mathematical impossibility.

To solve this, the agency has introduced the “Plausible Mechanism Pathway” (PMP) and the Rare Disease Evidence Principles (RDEP).

• Biological Logic over Headcount: The RDEP framework allows marketing authorization based on “biological plausibility.” If a drug can clearly demonstrate that it successfully “drugged” or edited its intended genetic target—confirmed by biomarkers or relevant non-clinical models—it can reach patients faster.
• The Case Study (Baby K.J.): This pathway was inspired by the 2025 case of an infant diagnosed with CPS1 deficiency, a fatal metabolic disorder. A bespoke CRISPR base-editing therapy was developed by teams at UPenn and CHOP in just six months. Because the therapy directly corrected the single-letter genetic mutation, the FDA approved the trial in just one week, bypassing years of standard multi-stage testing.
• Advancing RWE Program: Instead of delaying access for a decade of trials, the FDA uses the Advancing Real-World Evidence (RWE) Program to allow earlier market entry.
  • Example (Brineura): Historically, the FDA approved Brineura for Batten disease using a “single-arm” study where 22 treated children were compared against a natural history cohort of 42 untreated patients. This model—using real-world data from historical registries rather than a placebo group—is now the 2026 standard for ultra-rare approvals.
• Manufacturing Agility: Pioneers like David Liu have pushed the FDA to waive redundant manufacturing requirements. Currently, demonstrating three full-scale manufacturing runs can cost an extra $14 million—a prohibitive expense when a single run can often treat every patient in the world for a specific ultra-rare disease.

What This Means for the U.S. Rare Disease Ecosystem

Taken together, these reforms mark a decisive shift in how the United States competes in rare disease innovation. By prioritizing biological logic, real-world evidence, and manufacturing agility over traditional trial scale, the FDA is effectively turning regulatory flexibility into a national advantage. This approach allows the U.S. to move faster than jurisdictions bound by cost-effectiveness thresholds or rigid trial requirements, while keeping high-value genomic data, manufacturing, and intellectual property anchored domestically. In a field where speed determines survival—for patients and companies alike—the Rare Disease Innovation Hub positions the U.S. not just as a discovery leader, but as the rule-setter for how rare disease medicines are developed, evaluated, and scaled globally.

The Economic Landscape: Cost, Value, and Strategic Moats

The financial stakes in North America are immense. The global rare disease market is expected to hit $271 billion in 2026, with North America controlling over 41% of that share. While launch prices often exceed $370,000 annually, the market is shifting toward “one-and-done” curative models.

Companies like Johnson & Johnson (holding an 11% market share) and Eli Lilly articulated strategies that treat rare disease assets as “defensive moats” against patent cliffs. By focusing on areas with high unmet need, these firms secure premium pricing and long-term reimbursement, effectively de-risking their portfolios against generic competition.

Viewed through this lens, rare disease economics are less about headline drug prices and more about structural resilience. In an era of looming patent expirations and rising R&D risk, rare disease assets offer U.S. firms a uniquely durable value proposition: smaller, defensible markets protected by regulatory exclusivity, clearer reimbursement pathways, and reduced exposure to generic erosion. This makes rare diseases not just high-margin opportunities, but strategic moats that stabilize portfolios and justify continued domestic investment in advanced manufacturing and genomic innovation. The result is a market where cost, value, and national competitiveness are increasingly aligned—reinforcing why rare diseases have become central to the U.S. life sciences playbook.

The Information Gap: Data Silos and AI Solutions

While regulatory flexibility has lowered the evidentiary bar, data fragmentation has emerged as the new limiting factor in rare disease innovation. The “fragmentation of information” remains a primary hurdle. In North America, genomic data is often locked within proprietary systems. This proliferation of data silos makes it nearly impossible to perform the comprehensive analyses needed to understand the “natural history” of a disease. In North America, genomic, phenotypic, imaging, and longitudinal outcome data remain scattered across hospital systems, payers, academic registries, and commercial labs—often governed by incompatible standards and proprietary incentives. This fragmentation undermines one of the FDA’s core requirements for rare disease approvals: a robust understanding of natural history, progression rates, and meaningful endpoints.

What has changed in 2026 is not merely the availability of AI tools, but the convergence of regulatory acceptance and data infrastructure maturity. Agentic AI systems are now being deployed not just to analyze data, but to actively orchestrate it—querying heterogeneous datasets, flagging inconsistencies, and dynamically constructing disease-specific cohorts that would have taken human teams years to assemble.

Automation as Evidence Compression:

In rare diseases, where patient numbers are measured in dozens rather than thousands, the bottleneck is no longer signal detection but documentation density. AI-enabled “virtual trial” systems are compressing years of observational data into regulator-ready evidence packages—mapping biomarkers to outcomes, aligning registry data with EHRs, and generating traceable audit trails that satisfy FDA scrutiny without inflating trial size.

Decentralization as Population Expansion:

By linking EHRs, claims data, and remote monitoring tools, decentralized trial models are effectively expanding the usable patient population without expanding geography. This shift is particularly consequential for ultra-rare diseases, where patients are dispersed across states and provinces. In practice, it transforms every connected home into a longitudinal data node—reducing selection bias, accelerating recruitment, and enabling continuous post-approval surveillance aligned with the FDA’s Real-World Evidence mandate.

Taken together, these advances are redefining competitive advantage in rare diseases. The leaders will not be those with the most sophisticated gene-editing tools, but those who can integrate biology, data, and regulation into a single evidentiary pipeline. In 2026, mastery of data architecture is becoming as critical as mastery of molecular design—shaping who can move fastest, scale sustainably, and ultimately set the standards for rare disease care.

The Global Conundrum: Competing on Rules, Not Cost

The urgency behind these reforms reflects a shifting global balance in biotechnology. China’s rapid expansion—from a few hundred biotech firms to more than 4,000 in a decade—has been fueled by lower trial costs, streamlined approvals, and aggressive state coordination. For multinational developers, this has made China an increasingly attractive venue for late-stage trials, where a Phase 3 study can cost a fraction of its U.S. equivalent.

Yet the U.S. response in 2026 is not to mirror this cost competition, but to redefine the terms of leadership. Rather than chasing scale through cheaper trials, Washington is betting on a regulatory model that privileges biological insight, data integration, and speed to patient access. The Rare Disease Innovation Hub, real-world evidence frameworks, and acceptance of small-population and “n-of-1” data are designed to keep discovery, validation, and manufacturing anchored domestically—while setting global expectations for how next-generation therapies should be evaluated.

This approach reflects a broader recalibration of American biomedical strategy. Rare diseases are no longer treated as regulatory exceptions or niche markets, but as testbeds for a new model of precision regulation—one capable of absorbing CRISPR, mRNA, and AI-driven medicine at scale. In doing so, the U.S. is positioning rare disease policy not only as a humanitarian imperative, but as a mechanism for retaining scientific sovereignty and shaping the future rules of global medicine.

Across North America, the frontier is becoming increasingly bespoke—but also increasingly systematic. The central challenge is no longer scientific feasibility, but institutional alignment: ensuring that regulatory systems, data infrastructure, capital markets, and clinical practice evolve together. If successful, the reforms now underway could turn rare disease innovation from an exception-driven exercise into a durable, exportable model—one where speed, rigor, and patient impact coexist, and where a 30% childhood mortality rate becomes a historical artifact rather than a persistent reality.

Author

Bernice Lottering